Interferon alfa2a in the treatment of exudative age. Ten eyes were randomized to subcutaneous interferon alpha2a 3 million unitsm 2 every other day for 8 weeks, whereas 10 eyes were randomized to observation alone as controls. Pharmacological therapy for macular degeneration study group. Interferon alfa is one antiangiogenic agent thought to function by inhibiting the migration and proliferation of vascular endothelial cells. This case report displays the potential efficacy and safety of interferon alpha 2b in the treatment of refractory cystoid macular edema after cataract surgery. Interferon alpha 2a for treatment of agerelated macular degeneration.
Regarding gamma and alpha ifn, the serum levels were not. It has recently been suggested that interferon alpha2a has a beneficial effect on exudative agerelated macular degeneration amd. Novartis slammed by warning on macular degeneration drug. Forty eight eyes of 42 patients with choroidal neovascular membranes and agerelated macular degeneration who received three different dose regimens of systemic interferon alfa2.
Results of a prospective randomized placebocontrolled clinical trial. Pdf topical interferon alpha 2b in the treatment of. Nineteen patiens 20 eyes with the exudative form of macular degeneration were treated with parenteral interferon alfa2a. Macular degeneration macular degeneration is a disorder that affects the central part of the retina of the eye called the macula. Interferon alpha 2a treatment of patients with subfoveal neovascular macular degeneration. Topical interferon alpha 2b in the treatment of refractory. The retinopathy was first diagnosed 2 to 16 weeks after the start of treatment and. Interferon alpha 2a has been shown to be beneficial in certain types of agerelated macular degeneration treatments by reducing subfoveal choroidal neovascular membranes cnv, in. Interferon alpha2a for subfoveal neovascularization in agerelated.
Here a pilot study is reported in which 10 patients with exudative agerelated macular degeneration armd have been treated with a course of interferon injections. Interferon alfa for the treatment of neovascular age. The average followup was 8 months range 511 months. Interferon alfa2a is ineffective for patients with. Ocular complications with highdose interferon alpha in chronic. For hepatitis c it is typically used together with ribavirin and cure rates are between 24 and 92%. Purpose interferon alpha, which is used to treat various systemic disorders, has many reversible. Evaluation of serum interferons in patients with agerelated macular. Treatment of choroidal neovascularisation in agerelated macular. Interferon alpha2a treatment of patients with subfoveal. At the 2month followup visit, the interferon group manifested.
To evaluate the safety and efficacy of interferon alfa2a for the treatment of choroidal neovascularization secondary to agerelated macular degeneration. Interferon alfa2a is ineffective for patients with choroidal. Fluorescein angiography, bestcorrected visual acuity tests, and macular visual field assessments were performed, and all eyes were followed for a minimum of 6 months. In this case report, we employed topical interferon.
Treatment of choroidal neovascularisation in agerelated. Fifteen patients 16 eyes had adequate followup for evaluation of outcome of the exudative macular lesion. Department of internal medicine ii, university of tubingen. Pegylated interferon alfa2a, sold under the brand name pegasys among others, is medication used to treat hepatitis c and hepatitis b. Interferon alpha2a for subfoveal neovascularization in.
Ocular changes due to systemic alphainterferon therapy for. Interferonassociated retinopathy jama ophthalmology jama. Retinal circulatory changes associated with interferoninduced. Interferon alpha 2a has been shown to be beneficial in certain types of agerelated macular degeneration treatments by reducing subfoveal choroidal neovascular membranes cnv, in lesions not treatable with laser therapy. Macular degeneration is a disorder that affects the central part of the retina of the eye called the macula. It has been used in the treatment of hepatitis, solid tumors and hematologic malignancies. So far, results are controversial, and masked, placebo controlled, randomized studies with welldefined inclusion criteria are required to assess the effect of interferon alpha2a.
It causes decreased vision and loss of central vision. Interferon alpha2a for proliferative diabetic retinopathy. Forty eight eyes of 42 patients with choroidal neovascular membranes and agerelated macular degeneration who received three different dose regimens of systemic interferon alfa 2 were studied retrospectively. There has been recent interest in the use of systemic interferon alfa2a treatment for choroidal neovascular membranes cnv. Interferon alfa2a in the treatment of exudative agerelated macular degeneration. Uveitis, cystoid macular edema, treatment, interferon alpha. Interferon alpha2a for subfoveal neovascularization in agerelated macular. The efficacy of intravitreal interferon alpha2b for the treatment of. Clinical experience with interferon alfa2a for exudative.